Author: Casanova, Victor; Sousa, Filipa H; Stevens, Craig; Barlow, Peter G
Title: Antiviral therapeutic approaches for human rhinovirus infections Document date: 2018_6_12
ID: kl7holv4_27
Snippet: Drugs based on Poly I:C or derivatives are being developed as broad-spectrum antivirals and potential adjuvants for DC-targeted vaccines. Poly I:C stabilized with poly-l-lysine and carboxymethylcellulose, known as poly-ICLC, has shown efficacy against viruses such as influenza [129] and is also being tested in an HIV vaccine trial (Oncovir, Inc. and Dalton Pharma Services, ON, Canada). PIKA (NewBiomed PIKA Pte Ltd, Singapore), a chemically stabil.....
Document: Drugs based on Poly I:C or derivatives are being developed as broad-spectrum antivirals and potential adjuvants for DC-targeted vaccines. Poly I:C stabilized with poly-l-lysine and carboxymethylcellulose, known as poly-ICLC, has shown efficacy against viruses such as influenza [129] and is also being tested in an HIV vaccine trial (Oncovir, Inc. and Dalton Pharma Services, ON, Canada). PIKA (NewBiomed PIKA Pte Ltd, Singapore), a chemically stabilized analog of Poly I:C also reduced influenza virus load in the lungs of infected mice [130] . While its antiviral effects hold promise for treatment of RV infection, delivery of Poly I:C can, in some instances, lead to increased bacterial replication (Mycobacterium tuberculosis, Streptococcus pneumoniae and Staphylococcus aureus) and impaired clearance from the lungs due to prolonged interferon signaling [131, 132] . Given that RV is frequently associated with increased secondary bacterial infections, especially in individuals with chronic obstructive pulmonary disease or other underlying morbidities, further work is required to determine whether Poly I:C or stabilized analogs are safe as antiviral therapeutics for RV infection.
Search related documents:
Co phrase search for related documents- antiviral effect and bacterial replication: 1, 2, 3
- antiviral effect and broad spectrum: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50
- antiviral effect and broad spectrum antiviral: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34
- antiviral effect and DC target: 1
- antiviral effect and impaired clearance: 1
- antiviral effect and infected mouse: 1, 2, 3, 4, 5
- antiviral effect and influenza virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59
- antiviral effect and influenza virus load: 1
- antiviral effect and mycobacterium tuberculosis: 1
- antiviral effect and obstructive pulmonary disease: 1, 2
- antiviral effect and potential adjuvant: 1, 2, 3, 4
- antiviral effect and pulmonary disease: 1, 2
- antiviral effect and rv infection: 1, 2
- antiviral effect and Staphylococcus aureus: 1, 2, 3
- antiviral therapeutic and bacterial infection: 1, 2
- antiviral therapeutic and broad spectrum: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32
- antiviral therapeutic and broad spectrum antiviral: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- antiviral therapeutic and influenza virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47
- antiviral therapeutic and mycobacterium tuberculosis: 1
Co phrase search for related documents, hyperlinks ordered by date